Table 5 |
|
|
Respondents with clinical measurements associated with vascular risk |
|
|
Blood pressure levels and anti-hypertensive treatment |
Percentage (95% CI) |
|
|
|
|
Normal blood pressure, no treatment |
57.1% (51.8, 62.3) |
|
High blood pressure, no pharmacological treatment |
32.6% (27.8, 37.7) |
|
JNC7 Stage 1 high blood pressure, no pharmacological treatment |
17.6% (13.8, 21.9) |
|
JNC7 Stage 2 high blood pressure, no pharmacological treatment |
15.0% (11.5, 19.2) |
|
On pharmacological treatment for high blood pressure |
10.3% (7.3, 13.9) |
|
Normal blood pressure on pharmacological treatment |
5.29% (3.21, 8.14) |
|
JNC7 Stage 1 high blood pressure, on pharmacological treatment |
2.79% (1.34, 5.06) |
|
JNC7 Stage 2 high blood pressure, on pharmacological treatment |
2.23% (0.967, 4.34) |
|
|
|
|
Lipid profilei |
|
|
Total cholesterol > 5.0 mmol/l |
25.6 (20.4, 31.2) |
|
HDL cholesterol < 1.2 mmol/l |
22.2 (17.3, 27.7) |
|
HDL:total cholesterol ≥ 20%ii |
93.5 (89.9, 96.2) |
|
|
|
|
i no-one was using treatment to lower cholesterol levels. ii excluding 3 men with an HDL cholesterol at or above 3 mmol/l |
|
|
Thorogood et al. BMC Public Health 2007 7:326 doi:10.1186/1471-2458-7-326 |
|
